Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation

B. Degertekin, Steven Huy B Han, E. B. Keeffe, Eugene R Schiff, V. A. Luketic, R. S. Brown, S. Emre, C. Soldevila-Pico, K. R. Reddy, M. B. Ishitani, T. T. Tran, T. L. Pruett, A. S F Lok

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the rate of HBV recurrence after orthotopic liver transplantation (OLT) in relation to virologic breakthrough pre-OLT and HBIG regimens post-OLT. Data from the NIH HBV-OLT database were analyzed. A total of 183 patients transplanted between 2001 and 2007 followed for a median of 42 months (range 1-81) post-OLT were studied. At transplant, 29% were hepatitis B e antigen (HBeAg) (+), 38.5% had HBV DNA > 5 log10 copies/mL, 74% were receiving antiviral therapy. Twenty-five patients experienced virologic breakthrough before OLT. Post-OLT, 26%, 22%, 40% and 12% of patients received intravenous (IV) high-dose, IV low-dose, intramuscular low-dose and a finite duration of HBIG, respectively as maintenance prophylaxis. All but two patients also received antiviral therapy. Cumulative rates of HBV recurrence at 1 and 5 years were 3% and 9%, respectively. Multivariate analysis showed that listing HBeAg status and HBV DNA level at OLT were the only factors associated with HBV recurrence. In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre- and post-OLT.

Original languageEnglish
Pages (from-to)1823-1833
Number of pages11
JournalAmerican Journal of Transplantation
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Hepatitis B
Liver Transplantation
Hepatitis
Immunoglobulins
Hepatitis B virus
Recurrence
Antiviral Agents
Hepatitis B e Antigens
Therapeutics
DNA
Multivariate Analysis
Maintenance
Databases
Transplants

Keywords

  • Adefovir
  • antiviral resistance
  • HBV DNA
  • hepatitis B e antigen
  • lamivudine

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation. / Degertekin, B.; Han, Steven Huy B; Keeffe, E. B.; Schiff, Eugene R; Luketic, V. A.; Brown, R. S.; Emre, S.; Soldevila-Pico, C.; Reddy, K. R.; Ishitani, M. B.; Tran, T. T.; Pruett, T. L.; Lok, A. S F.

In: American Journal of Transplantation, Vol. 10, No. 8, 01.08.2010, p. 1823-1833.

Research output: Contribution to journalArticle

Degertekin, B, Han, SHB, Keeffe, EB, Schiff, ER, Luketic, VA, Brown, RS, Emre, S, Soldevila-Pico, C, Reddy, KR, Ishitani, MB, Tran, TT, Pruett, TL & Lok, ASF 2010, 'Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation', American Journal of Transplantation, vol. 10, no. 8, pp. 1823-1833. https://doi.org/10.1111/j.1600-6143.2010.03046.x
Degertekin, B. ; Han, Steven Huy B ; Keeffe, E. B. ; Schiff, Eugene R ; Luketic, V. A. ; Brown, R. S. ; Emre, S. ; Soldevila-Pico, C. ; Reddy, K. R. ; Ishitani, M. B. ; Tran, T. T. ; Pruett, T. L. ; Lok, A. S F. / Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation. In: American Journal of Transplantation. 2010 ; Vol. 10, No. 8. pp. 1823-1833.
@article{e24e749f2a714efa89c5672b47a25d8d,
title = "Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation",
abstract = "The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the rate of HBV recurrence after orthotopic liver transplantation (OLT) in relation to virologic breakthrough pre-OLT and HBIG regimens post-OLT. Data from the NIH HBV-OLT database were analyzed. A total of 183 patients transplanted between 2001 and 2007 followed for a median of 42 months (range 1-81) post-OLT were studied. At transplant, 29{\%} were hepatitis B e antigen (HBeAg) (+), 38.5{\%} had HBV DNA > 5 log10 copies/mL, 74{\%} were receiving antiviral therapy. Twenty-five patients experienced virologic breakthrough before OLT. Post-OLT, 26{\%}, 22{\%}, 40{\%} and 12{\%} of patients received intravenous (IV) high-dose, IV low-dose, intramuscular low-dose and a finite duration of HBIG, respectively as maintenance prophylaxis. All but two patients also received antiviral therapy. Cumulative rates of HBV recurrence at 1 and 5 years were 3{\%} and 9{\%}, respectively. Multivariate analysis showed that listing HBeAg status and HBV DNA level at OLT were the only factors associated with HBV recurrence. In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre- and post-OLT.",
keywords = "Adefovir, antiviral resistance, HBV DNA, hepatitis B e antigen, lamivudine",
author = "B. Degertekin and Han, {Steven Huy B} and Keeffe, {E. B.} and Schiff, {Eugene R} and Luketic, {V. A.} and Brown, {R. S.} and S. Emre and C. Soldevila-Pico and Reddy, {K. R.} and Ishitani, {M. B.} and Tran, {T. T.} and Pruett, {T. L.} and Lok, {A. S F}",
year = "2010",
month = "8",
day = "1",
doi = "10.1111/j.1600-6143.2010.03046.x",
language = "English",
volume = "10",
pages = "1823--1833",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation

AU - Degertekin, B.

AU - Han, Steven Huy B

AU - Keeffe, E. B.

AU - Schiff, Eugene R

AU - Luketic, V. A.

AU - Brown, R. S.

AU - Emre, S.

AU - Soldevila-Pico, C.

AU - Reddy, K. R.

AU - Ishitani, M. B.

AU - Tran, T. T.

AU - Pruett, T. L.

AU - Lok, A. S F

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the rate of HBV recurrence after orthotopic liver transplantation (OLT) in relation to virologic breakthrough pre-OLT and HBIG regimens post-OLT. Data from the NIH HBV-OLT database were analyzed. A total of 183 patients transplanted between 2001 and 2007 followed for a median of 42 months (range 1-81) post-OLT were studied. At transplant, 29% were hepatitis B e antigen (HBeAg) (+), 38.5% had HBV DNA > 5 log10 copies/mL, 74% were receiving antiviral therapy. Twenty-five patients experienced virologic breakthrough before OLT. Post-OLT, 26%, 22%, 40% and 12% of patients received intravenous (IV) high-dose, IV low-dose, intramuscular low-dose and a finite duration of HBIG, respectively as maintenance prophylaxis. All but two patients also received antiviral therapy. Cumulative rates of HBV recurrence at 1 and 5 years were 3% and 9%, respectively. Multivariate analysis showed that listing HBeAg status and HBV DNA level at OLT were the only factors associated with HBV recurrence. In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre- and post-OLT.

AB - The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the rate of HBV recurrence after orthotopic liver transplantation (OLT) in relation to virologic breakthrough pre-OLT and HBIG regimens post-OLT. Data from the NIH HBV-OLT database were analyzed. A total of 183 patients transplanted between 2001 and 2007 followed for a median of 42 months (range 1-81) post-OLT were studied. At transplant, 29% were hepatitis B e antigen (HBeAg) (+), 38.5% had HBV DNA > 5 log10 copies/mL, 74% were receiving antiviral therapy. Twenty-five patients experienced virologic breakthrough before OLT. Post-OLT, 26%, 22%, 40% and 12% of patients received intravenous (IV) high-dose, IV low-dose, intramuscular low-dose and a finite duration of HBIG, respectively as maintenance prophylaxis. All but two patients also received antiviral therapy. Cumulative rates of HBV recurrence at 1 and 5 years were 3% and 9%, respectively. Multivariate analysis showed that listing HBeAg status and HBV DNA level at OLT were the only factors associated with HBV recurrence. In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre- and post-OLT.

KW - Adefovir

KW - antiviral resistance

KW - HBV DNA

KW - hepatitis B e antigen

KW - lamivudine

UR - http://www.scopus.com/inward/record.url?scp=77954944543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954944543&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2010.03046.x

DO - 10.1111/j.1600-6143.2010.03046.x

M3 - Article

C2 - 20346062

AN - SCOPUS:77954944543

VL - 10

SP - 1823

EP - 1833

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -